Videos

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.

In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based regimens into NCCN recommendations could influence future treatment sequencing.

In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients.

Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could improve patient quality of life.

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

Enrolling pediatric patients and identifying biomarkers for response are the priorities for research of ozekibart in Ewing sarcoma.

ZUMA-2 cohort 3 shows brexu-cel CAR T delivers 91% responses in mantle cell lymphoma, with manageable CRS/ICANS, driving full FDA approval.

Dr Richard Goldberg discusses how outdated FDA metrics may delay immunotherapy approvals for oncology agents.

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose testing and expanded eligibility, enabling full FDA approval.

Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient groups.

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a game-changing option.

Dr Saba emphasizes the prioritizing of rapid BRAF testing and surgical assessment in ATC workups.

Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma.

Dr Raj Singh discusses radiation strategies, dose escalation, PCI debates, and multidisciplinary collaboration in small cell lung cancer management.

Dr. Costa concludes by emphasizing the transformative moment in multiple myeloma therapy, with rapidly increasing agents demonstrating incredible efficacy alongside accelerated newer class development.

ASCO's updated thyroid cancer guidelines help clinicians navigate rapidly evolving systemic therapies, from VEGF inhibitors to BRAF-targeted agents.

Rashmi Chugh, MD, describes the background for a study of ozekibart in Ewing sarcoma.

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork improves outcomes.

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the way for future self-administration.

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ROS1-positive metastatic NSCLC.

In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on the clinical scenarios in which cabozantinib is selected following progression on first-line therapy.

In this segment on advanced renal cell carcinoma, Dr. Wulff transitions the discussion to treatment sequencing after progression on first-line IO-based therapy.

Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse detection and tailored care.

Dr Christine Bestvina discusses EGFR treatment shifts, expanding community clinical trial access, and upcoming KRAS G12C and neoadjuvant therapy data.

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and expanding access for rural patients.

On-body isatuximab injection matches IV results in relapsed multiple myeloma, with similar safety, drug levels, and better convenience.

Discover ways to detect early-onset cancers sooner, avoid age bias, and coordinate multidisciplinary care, fertility, genetics, and support.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer patients from the RUBY trial.

MSK researchers found that BRCA2 mutations lower the barrier for RB1 loss, causing CDK4/6 inhibitor resistance.

New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter second-line sequencing.